Loading...
Market
What will be the market share of Kisunla™ among Alzheimer's treatments by end of 2024?
2
Resolution / Starting Odds
Below 10% • 33%
10-20% • 33%
Above 20% • 33%
Market analysis reports from firms like IQVIA or Frost & Sullivan
Story
Eli Lilly's Kisunla™ Receives FDA Approval for Early Symptomatic Alzheimer's Treatment
Jul 2, 2024, 05:39 PM
Eli Lilly's Kisunla™ (donanemab-azbt) has received FDA approval for the treatment of early symptomatic Alzheimer's disease. The new amyloid-targeting therapy is designed to slow cognitive decline by up to 35% and reduce the risk of disease progression. Kisunla™ is the second drug cleared in the US to slow the progression of Alzheimer's, a condition affecting 6 million Americans. The treatment involves 13 30-minute infusions over 12 months, costing $32,000. Eli Lilly intends to donate Kisunla™ to the Lilly Cares Foundation.
View original story
Similar markets
Kisunla > 50% • 25%
Kisunla 30-50% • 25%
Kisunla 10-30% • 25%
Kisunla < 10% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
21% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31%+ • 25%
Less than $100 million • 25%
$100 million - $299 million • 25%
$300 million - $499 million • 25%
$500 million or more • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
< 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
> 30% • 25%